Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.

@article{MajkowskaSkrobek2014KillingMM,
  title={Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.},
  author={Grażyna Majkowska-Skrobek and Daria Augustyniak and Paweł Lis and Anna Bartkowiak and Mykhailo Gonchar and Young Hee Ko and Peter L. Pedersen and A. Goffeau and Stanisław Ułaszewski},
  journal={Anti-cancer drugs},
  year={2014},
  volume={25 6},
  pages={673-82}
}
The small molecule 3-bromopyruvate (3-BP), which has emerged recently as the first member of a new class of potent anticancer agents, was tested for its capacity to kill multiple myeloma (MM) cancer cells. Human MM cells (RPMI 8226) begin to lose viability significantly within 8 h of incubation in the presence of 3-BP. The Km (0.3 mmol/l) for intracellular accumulation of 3-BP in MM cells is 24 times lower than that in control cells (7.2 mmol/l). Therefore, the uptake of 3-BP by MM cells is… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS